Esperion Therapeutics Inc. logo

Esperion Therapeutics Inc. (ESPR)

Market Open
14 Jul, 13:31
NASDAQ (NMS) NASDAQ (NMS)
$
3. 18
0
0%
$
661.15M Market Cap
- P/E Ratio
- Div Yield
59.09M Volume
-1.97 Eps
$ 3.18
Previous Close
Add Transaction
Day Range
3.18 3.18
Year Range
1.1 4.18
Want to track ESPR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
3 Penny Stocks to Buy if You Want to Spend Less and Earn More

3 Penny Stocks to Buy if You Want to Spend Less and Earn More

Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify their portfolios without breaking the bank.

Investorplace | 2 years ago
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?

Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Zacks | 2 years ago
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.

Zacks | 2 years ago
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance.

Seekingalpha | 2 years ago